Indian Journal of Pharmacology Home 

SHORT COMMUNICATION
[View FULLTEXT] [Download PDF]
Year : 2022  |  Volume : 54  |  Issue : 2  |  Page : 126--130

Pharmacological evaluation of embelin - chitosan nanoparticles as an antidiabetic agent

Saba Maanvizhi1, Narayanaswamy Radhakrishnan2, Chitra Krishnan4, Arumugam Gnanamani3 
1 Associate Professor, Sri Ramachandra Faculty of Pharmacy, Sri Ramachandra Institute of Higher Education and Research (Deemed University), Porur, Tamil Nadu, India
2 Professor and Head, Department of Biochemistry, St. Peter's Institute of Higher Education and Research, Avadi, Tamil Nadu, India
3 Sr. Principal Scientist, Head & Professor – AcSIR, Microbiology Division, Central Leather Research Institute, Adyar, Chennai, Tamil Nadu, India

Correspondence Address:
Dr. Arumugam Gnanamani
Microbiology Division, Central Leather Research Institute, Adyar, Chennai - 600 020, Tamil Nadu
India

Embelin has been reported to possess variety of pharmacological activities such as androgenic antagonists, antiangiogenic, antibacterial, anticancer, anticonvulsant, antidiabetic, antidepressant, antihelmintic, antifertility, antihyperlipidemic, anti-inflammatory, antimalarial, antimitotic, antiobesity and antioxidant properties. The current research work aimed to study the hypoglycemic effect of embelin-chitosan nanoparticles (ECNPs) diabetic rats provoked by streptozotocin (STZ). Embelin nanoparticles (ENPs) were created by combining chitosan, a natural biopolymer, and glutaric acid, a new cross-linker. STZ 50 mg/kg was given intravenously into Sprague-Dawley rats weighing 250–300 g (75–90 days) to induce experimental diabetes. The antidiabetic efficacy of orally administered ECNPs in diabetic rats developed by STZ was investigated, as well as histological examination. When compared to diabetic control rats, ECNPs (25 mg/kg body weight and 50 mg kg body weight) and standard glibenclamide (10 mg/kg body weight) treated rodents exhibited a remarkable drop in glucose contents. Furthermore, histological research showed that ECNPs-treated rats were harmless up to amount of 25 mg/kg bwt. Thus current investigation reveals that ECNPs have antidiabetic potential and may be beneficial in treating hyperglycemia in people.


How to cite this article:
Maanvizhi S, Radhakrishnan N, Krishnan C, Gnanamani A. Pharmacological evaluation of embelin - chitosan nanoparticles as an antidiabetic agent.Indian J Pharmacol 2022;54:126-130


How to cite this URL:
Maanvizhi S, Radhakrishnan N, Krishnan C, Gnanamani A. Pharmacological evaluation of embelin - chitosan nanoparticles as an antidiabetic agent. Indian J Pharmacol [serial online] 2022 [cited 2022 Jul 6 ];54:126-130
Available from: https://www.ijp-online.com/article.asp?issn=0253-7613;year=2022;volume=54;issue=2;spage=126;epage=130;aulast=Maanvizhi;type=0